Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 17/20 | 0.78 |
| ▸ | EZH1 | Q92800 | 6/20 | 0.78 |
| ▸ | EED | O75530 | 5/20 | 0.78 |
| ▸ | SUZ12 | Q15022 | 5/20 | 0.78 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.62 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.62 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19610318 | 0.92 | EZH2 (0.71) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL19477604 | 0.91 | EZH2 (0.67) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL19610320 | 0.90 | EZH2 (0.68) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL16360967 | 0.90 | EZH2 (0.80) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL19477539 | 0.88 | EZH2 (0.64) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL2594340 | 0.88 | EZH2 (0.78) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL18768926 | 0.88 | EZH2 (0.88) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL2594075 | 0.88 | EZH2 (1.00) | EZH2EZH1EEDSUZ12HDAC1 | |
| Gsk2816126 SCHEMBL12180401 | 0.87 | EZH2 (1.00) | EZH2EZH1EEDSUZ12HDAC1 | |
| Gsk2816126 SCHEMBL2595737 | 0.87 | EZH2 (1.00) | EZH2EZH1EEDSUZ12HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021080955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021080950-A1 | METHODS FOR TREATING A HEMATOLOGICAL CANCER AND THE USE OF COMPANION BIOMARKERS FOR 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | CELGENE CORPORATION (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2017201585-A1 | MODULATORS OF DUX4 FOR REGULATION OF MUSCLE FUNCTION | GENEA IP HOLDINGS PTY LTD (AU) | 2017-11-30 | — | — | WO | disclosed |